VANCOUVER, BC, Sept. 22, 2021 /CNW/ - Sirona Biochem Corp.
(TSXV: SBM) (FSE: ZSB) (USOTC:
SRBCF) ("Sirona") reports that In Vitro studies
completed on compounds developed by our scientists at TFChem have
shown a strong potential for anti-cellulite activity. The data
showed evidence for both the ability to reduce existing cellulite
and to prevent the formation of new cellulite. The mechanism of
action is technically complex involving a pro-lipolytic effect, a
decrease of the adipocyte size and an anti-inflammatory effect.
Sirona's Chief Scientific Officer, Dr. Géraldine
Deliencourt-Godefroy and her team have created a development plan
and will begin the safety testing required for a clinical trial.
Specific details of the compounds will be communicated immediately
following the filing of patents.
Cellulite is the development of orange-peel like skin,
particularly in the thigh and buttock area due to fat under the
skin and often develops further with aging. There are currently no
truly effective therapies to treat cellulite. The global market
size was valued at USD 1.4 Billion in
2020 and is expected to have a compounded annual growth rate of
11.0%.
Additionally, as follow up to the last quarterly report, our
pharmaceutical partner from the second clinical trial of TFC-1067
has successfully completed due diligence as scheduled. Follow up
discussions are scheduled in September to discuss next steps with
the goal of completing a long-term definitive agreement.
"We're very excited about this discovery in a valuable market.
Once again, the immense potential of our platform technology is
demonstrated. Our scientist will conduct ongoing analysis of this
discovery. At the same time management will continue to focus on
our current priority initiative of further partnering TFC-1067,"
said Dr. Howard Verrico, CEO. "With
respect to 1067, we are pleased to be at an advanced stage
following extensive due diligence and scientific research by our
clinical trial partner. We are looking forward to next steps with
great confidence."
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.